Event: Kindred Biosciences to Announce First Quarter 2016 Financial Results

Thursday, May 5, 2016

Time of Event: 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time

Telephone Dial in:  toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally
Conference ID: 98352561

For more information about this event, please see the press release.

  Read more

Event: Kindred Biosciences to Announce Fourth Quarter and Year-End 2015 Financial Results

Wednesday, March 2, 2016

Time of Event: 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time

Telephone Dial in:  toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally
Conference ID: 56547791.

For more information about this event, please see the press release.

  Read more

Kindred Biosciences Corporate Update via Webcast in Advance of One-on-One Investor Meetings in San Francisco January 12-14, 2016.

Monday, January 11, 2016

Time of Event: 8:30 AM Eastern Standard Time

 For more information on this event, please see the press release

Kindred Biosciences to Provide Corporate Update via Webcast in Advance of One-on-One Investor Meetings in San Francisco January 12-14, 2016.

San Francisco, CA (January 7, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will provide a corporate update via webcast on Monday, January 11, 2016 in advance of one-on-one investor meetings in San Francisco January 12-14, 2016. Read more

Kindred Biosciences Announces Positive Results from Pivotal Study of KIND-012 for Pyrexia in Horses, and Provides Other Product Updates

KIND-012 study meets primary endpoint with p<0.0001. Data to be filed with the FDA for approval. SentiKind study misses primary endpoint.

Conference call and webcast scheduled for 5:00 p.m. Eastern Time today.

San Francisco, CA (November 16, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pivotal field study (KB0120) of KIND-012 for the control of pyrexia (fever) in horses. Read more

Kindred Biosciences to Present at 2015 Jefferies Animal Health Summit

San Francisco, CA (March 19, 2015) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and Chief Operating Officer, will be presenting at the 2015 Jefferies Animal Health Summit in New York, NY on Thursday, March 26, 2015 at 1:30 PM EDT.

Read more

KindredBio to Announce Fourth Quarter and Year-End 2014 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, March 12, 2015

SAN FRANCISCO, California. (March 3, 2015) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its fourth quarter and year-end 2014 financial results on March 12, 2015 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time that day. Read more

KindredBio to Present at Jefferies 2014 Global London Healthcare Conference

SAN FRANCISCO, California. (November 17, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will be presenting at the 2014 Jefferies Global Healthcare Conference in London on Thursday, November 20, 2014 at 5:00 PM GMT. Read more

Top-Line Results from Pivotal Study of CereKin in Dogs with Osteoarthritis Conference Call

Wednesday, August 20, 2014
Time of call: 5:30pm ET/ 2:30pm PST

Participant Toll-free Dial-in number: (855) 433-0927
Participant International Dial-in number: (484) 756-4262
Conference ID: 91627369

KindredBio to Host Investor Breakfast on June 13 in New York City

SAN FRANCISCO, California. (June 11, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will host an Investor Breakfast on Friday, June 13, 2014 in New York City. KindredBio’s executive management team will provide an overview of the Company’s strategies and Stephen Sundlof, D.V.M, Ph.D., will offer insights into the animal health business from an FDA perspective.

Read more